Following a second injection at eight weeks, the patient maintained stable vision and remained dry at 12 weeks, allowing for ...
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today highlighted recent scientific ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Early-phase clinical trials involving PIM-1 kinase inhibitors look promising. In the evolving landscape of myelofibrosis (MF) ...
The dipeptidyl peptidase-1 (DPP1) inhibitor brensocatib became the first licensed therapy for bronchiectasis in the USA and Europe in 2025,1 based on the phase 3 ASPEN trial showing an approximate 20% ...
Mistakes, whether spoken or promised, are universal. The feeling of putting our foot in our mouth arises from a key executive function that our brain controls: stopping ourselves. However, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results